Bristol Myers: Opdivo Qvantig approved for subcutaneous use
(CercleFinance.com) - Bristol Myers Squibb reports that the US FDA has approved its Opdivo Qvantig injection for subcutaneous use in most of Opdivo's previouesly approved indications for solid tumors in adults.
Administered over three to five minutes, Opdivo Qvantig demonstrated consistent efficacy and a safety profile comparable to intravenous (IV) Opdivo in the phase 3 CheckMate-67T trial, the pharmaceutical company says.
Opdivo Qvantig is now the first and only PD-1 inhibitor administered subcutaneously, offering patients a faster option for receiving this immunotherapy treatment than Opdivo IV administered over 30 minutes.
The subcutaneous option can offer the flexibility to receive treatment where it's best for patients and their providers, and can reduce the steps required for preparation as well as the time needed for administration.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Administered over three to five minutes, Opdivo Qvantig demonstrated consistent efficacy and a safety profile comparable to intravenous (IV) Opdivo in the phase 3 CheckMate-67T trial, the pharmaceutical company says.
Opdivo Qvantig is now the first and only PD-1 inhibitor administered subcutaneously, offering patients a faster option for receiving this immunotherapy treatment than Opdivo IV administered over 30 minutes.
The subcutaneous option can offer the flexibility to receive treatment where it's best for patients and their providers, and can reduce the steps required for preparation as well as the time needed for administration.
Copyright (c) 2024 CercleFinance.com. All rights reserved.